2. UroToday Home
  3. Video Lectures

ASCO 2023

Tumour Factors and the Variation in Non-Muscle Invasive Bladder Cancer Recurrence After Transurethral Resection Surgery Between Sites: Results from the RESECT Study - Kevin Gallagher
A Deep Dive into Patient Experiences in Prostate Cancer Clinical Trials - Ravi Madan
KEYNOTE-B61 Study Reveals Promising Results of Lenvatinib + Pembrolizumab Combo in Non-Clear Cell RCC - Chung-Han Lee
EV-103 Study Update: Four-Year Data on Enfortumab Vedotin and Pembrolizumab Combination in Urothelial Cancer - Shilpa Gupta
DDR and PARP Inhibition: What's the Damage? - David VanderWeele
Prospective Monitoring of Biochemical Recurrence with PSMA PET - Ravi Madan
The Radiopharmaceutical Revolution: New Frontiers in Prostate Cancer Treatment - Oliver Sartor
Prostate Cancer and Veterans Health: A Spotlight on the Initiatives at the VA System - Hiten Patel
Patient-Driven Webtool Challenges Traditional Counseling in Prostate Cancer Germline Testing - Veda Giri
Detecting Early Testicular Cancer Relapse with Plasma MicroRNA Analysis - Lucia Nappi
PSMA-PET Implications for Extent and Survival Outcomes in High-Risk nmCRPC: An International Study - Boris Hadaschik
Analyzing Quality of Life and Survival from CHAARTED Prostate Cancer Trial - Daniel Sentana Lledo
Primary Analysis of STARTAR: A Phase 2 Salvage Trial for High-Risk Prostate Cancer with Biochemical Recurrence - Tian Zhang
Outcomes with Immune Checkpoint Inhibitors in Patients with MTAP Alterations in Advanced Urothelial Carcinoma - Rafee Talukder
Hospital Anxiety and Depression Scale (HADS) Score Trends Among Testicular Cancer Survivors: a Longitudinal Study - Khalid Alkhatib
Association of Plant-Based Diet Index with Quality of Life in Patients with Prostate Cancer - Stacy Loeb
The SAMURAI Study's Role in Evolving Radiation Therapy for Kidney Cancer - Rana McKay & William Hall
Cancer Care's Hidden Burden: Linking Financial Stress and Mortality in Cancer Treatment - Hiba Khan
Genomic Alterations and Self-Reported Agent Orange Exposure in United States Veterans with Metastatic Prostate Cancer - JJ Haijing Zhang
Innovation in Prostate Cancer Care: Frailty, Bone Health, and Cardiovascular Screening - Ravi B. Parikh
Enfortumab Vedotin Combination Therapy and Response Rates - Jonathan E. Rosenberg
The Relationship Between a Priori Defined Prognostic Risk Groups and Overall Survival in Men with mCRPC - Susan Halabi
Understanding Erectile Dysfunction: Patient Education and Personalized Treatment - Jeffrey Albaugh
A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in mHSPC: A-DREAM - Atish D. Choudhury
Early Aggressive Treatment Shows Promise for Prostate Cancer Recurrence - Stephen J. Freedland
Prostate Cancer Survivorship Today: Support that Spans the Journey - Alicia Morgans
Understanding BRCA Mutations: The Pivotal Impact of the CAPTURE Study - David Olmos
PSMA PET's Influence on Prostate Cancer Studies - Jeremie Calais
Harnessing Exercise to Improve Outcomes in Black Prostate Cancer Patients - Dong-Woo (Derek) Kang
Navigating Salvage Radiotherapy with Insights from PSMA PET - Jeremie Calais
Predictive Modeling for 177Lu-PSMA-617 Therapy in Patients with mCRPC - Ken Herrmann
Unlocking Prostate Cancer Treatment: The Pathway of CAR T Targeting Prostate Stem Cell Antigen - Tanya Dorff
From Trial to Treatment: Exploring the Lasting Impact of KEYNOTE-426 in Kidney Cancer - Brian Rini
Promising Results: Cohort Two of TALAPRO-2 Study Reveals Insights and Potential Breakthroughs in Prostate Cancer Treatment - Karim Fizazi
From the VISION Trial: Improved Patient Outcomes with Lutetium-PSMA-617 - Karim Fizazi
Beyond BRCA-1 and 2: The Impact of the TALAPRO-2 Study on Prostate Cancer Care - Cora Sternberg
Exploring Novel Emitter Combinations in Prostate Cancer Research - Scott Tagawa
The Prognostic Value of PSA Levels Post-Radiation in Prostate Cancer - Praful Ravi
Efficacy over Cost: Unpacking Kidney Cancer Patients' Therapy Selection Priorities - Dena Battle
Exploring Racial Biases in Clinical Trials: The PANTHER Study's Findings on Prostate Cancer - Dan George
Deciphering Immunotherapy Responses in Advanced RCC: A Deep Dive into the HCRN Study - Nourhan El Ahmar
Addressing the Gaps in Quality of Life: A New Measure for Renal Cell Carcinoma Patients - Cristiane Bergerot
Exploring Acupuncture's Potential to Mitigate BCG Therapy Side Effects: A Phase I/II Trial - Sarah Psutka
Interpreting EMBARK Trial Results: Intensified Treatment and Hormone Therapy in High-Risk Patients - Christian Gratzke
Navigating the Future of Prostate Cancer Treatment and Global Access at APCCC 2024 - Silke Gillessen
Beyond Medical Advancements: Addressing Financial and Personal Challenges in Metastatic Castration-Sensitive Prostate Cancer Treatment - Neeraj Agarwal
Personalizing Prostate Cancer Therapy Using AI-based Predictive Biomarkers - Paul Nguyen
TALAPRO-2 Study Reveals Efficacy and Tolerability of Talazoparib Combination for Prostate Cancer - Neeraj Agarwal
Exploring Darolutamide's Impact on Time to Pain Progression Based on Disease Volume in the ARASENS Study - Matthew Smith
Prostate Cancer Treatment Revolution: Radiotherapy and Abiraterone in the Spotlight of PEACE-1 - Alberto Bossi